Program
valemetostat
Its studies are mostly in Prostatic Neoplasms, led by Daiichi Sankyo.
Furthest: phase 1, since Nov 17, 20251 company-led study, 1 open or runningNext primary completion: Jan 31, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daiichi Sankyo | 11 open or running | phase 1since Nov 17, 2025 | Nov 17, 2025 | Jan 31, 2028phase 1 · NCT07244341 |
Also a collaborator on its studies: Bayer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 17, 2025First study: phase 1 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT07244341 · 60 planned · United States, Australia, China and more
Ahead
- Jan 31, 2028Primary completion: phase 1 study in Metastatic Castration-resistant Prostate CancerNCT07244341
TargetBeta
“An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07244341Metastatic Castration-resistant Prostate Cancer · United States, Australia, China and more | 1 | Recruiting | Jan 31, 2028 | 60 |
How it is read
Names in the registry
- “Valemetostat”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.